Pharmacologic inhibitors of P2Y12 are widely used therapeutically for a number of pathologies ranging from cardiovascular diseases to stroke, and rates of resistance to therapeutic P2Y12 inhibition have been reported as high as 30% in patients treated with clopidogrel (83). Here, P2RY12 is linked to cardiovascular disorder.